65178-90-7Relevant articles and documents
Nucleophilic (Radio)Fluorination of Redox-Active Esters via Radical-Polar Crossover Enabled by Photoredox Catalysis
Webb, Eric W.,Park, John B.,Cole, Erin L.,Donnelly, David J.,Bonacorsi, Samuel J.,Ewing, William R.,Doyle, Abigail G.
supporting information, p. 9493 - 9500 (2020/05/18)
We report a redox-neutral method for nucleophilic fluorination of N-hydroxyphthalimide esters using an Ir photocatalyst under visible light irradiation. The method provides access to a broad range of aliphatic fluorides, including primary, secondary, and tertiary benzylic fluorides as well as unactivated tertiary fluorides, that are typically inaccessible by nucleophilic fluorination due to competing elimination. In addition, we show that the decarboxylative fluorination conditions are readily adapted to radiofluorination with [18F]KF. We propose that the reactions proceed by two electron transfers between the Ir catalyst and redox-active ester substrate to afford a carbocation intermediate that undergoes subsequent trapping by fluoride. Examples of trapping with O- and C-centered nucleophiles and deoxyfluorination via N-hydroxyphthalimidoyl oxalates are also presented, suggesting that this approach may offer a general blueprint for affecting redox-neutral SN1 substitutions under mild conditions.
ANTI-CANCER COMPOSITIONS AND METHODS OF USE
-
Paragraph 00241; 00251; 00266; 00403; 00412; 00426; 00427, (2020/07/25)
This invention is directed to anticancer compounds, pharmaceutical compositions comprising the same, methods of making anticancer compounds, and methods of treating cancer with compounds and pharmaceutical compositions.
Novel derivative of 2-[3-cyano-4-isobutoxyphenyl]-4-methylthiazol-5-formic acid, preparation method for novel derivative and application of novel derivative
-
Paragraph 0083; 0107-0109, (2017/01/23)
The invention provides a compound as shown in a formula (I), or a pharmaceutical salt of the compound or stereisomers of the compound. The formula (I) is as shown in the specification. The compound as shown in the formula (I), or the pharmaceutical salt of the compound or the stereisomers of the compound applied to preventing and treating hyperuricemia have more superior uric-acid-reducing effect and more excellent safety compared to those of febuxostat.
